Okla. Stat. tit. 63, § 63-1-533v1: Phenylketonuria, related inborn metabolic disorders

and other genetic or biochemical disorders - Educational and newborn

screening programs.

THIS TEXT EFFECTIVE UNTIL NOV. 1, 2024. FOR TEXT EFFECTIVE

BEGINNING NOV. 1, 2024, SEE OS 63-1-533v2.

A. The State Commissioner of Health shall provide, pursuant to

the provisions of Section 1-534 of this title, as technologies and

funds become available, an intensive educational and newborn

screening program among physicians, hospitals, public health nurses,

and the public concerning phenylketonuria, related inborn metabolic

disorders, and other genetic or biochemical disorders for which:

1. Newborn screening will provide early treatment and

management opportunities that might not be available without

screening; and

2. Treatment and management will prevent intellectual

disabilities and/or reduce infant morbidity and mortality.

B. This educational and newborn screening program shall include

information about:

1. The nature of the diseases;

2. Examinations for the detection of the diseases in infancy;

and

3. Follow-up measures to prevent the morbidity and mortality

resulting from these diseases.

C. For purposes of this section, "phenylketonuria" means an

inborn error of metabolism attributable to a deficiency of or a

defect in phenylalanine hydroxylase, the enzyme that catalyzes the

conversion of phenylalanine to tyrosine. The deficiency permits the

accumulation of phenylalanine and its metabolic products in the body

fluids. The deficiency can result in intellectual disabilities

(phenylpyruvic oligophrenia), neurologic manifestations (including

hyperkinesia, epilepsy, and microcephaly), light pigmentation, and

eczema. The disorder is transmitted as an autosomal recessive trait

and can be treated by administration of a diet low in phenylalanine.

D. The Commissioner shall promulgate any rules necessary to

effectuate the provision of this section.